Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

医学 贝伐单抗 内科学 福尔菲里 伊立替康 彭布罗利珠单抗 肿瘤科 西妥昔单抗 奥沙利铂 临床终点 结直肠癌 人口 生活质量(医疗保健) 癌症 实体瘤疗效评价标准 氟尿嘧啶 无进展生存期 微卫星不稳定性 临床研究阶段 化疗 临床试验 环境卫生 化学 生物化学 免疫疗法 等位基因 护理部 基因 微卫星
作者
Thierry André,Mayur M. Amonkar,Josephine M. Norquist,Kai-Keen Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J.A. Punt,Denis Smith,Rocio García‐Carbonero,Isabel Sevilla,Christelle de la Fouchardière,Fernando Rivera,Elena Élez,Luis A. Díaz,Takayuki Yoshino,Eric Van Cutsem,Ping Yang,Mohammed Z.H. Farooqui,Dung T. Le
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (5): 665-677 被引量:162
标识
DOI:10.1016/s1470-2045(21)00064-4
摘要

In the KEYNOTE-177 study, pembrolizumab monotherapy provided statistically significant and clinically meaningful improvements in progression-free survival versus chemotherapy as first-line treatment in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. To further support the efficacy and safety findings of the KEYNOTE-177 study, results of the health-related quality of life (HRQOL) analyses are reported here.KEYNOTE-177 is an open-label, randomised, phase 3 trial being done at 192 cancer centres in 23 countries, in patients aged 18 years and older with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and who had not received previous systemic therapy for metastatic disease. Eligible patients were randomly assigned (1:1) centrally by use of interactive voice response or integrated web response technology to receive pembrolizumab 200 mg intravenously every 3 weeks or investigator's choice chemotherapy (mFOLFOX6 [leucovorin, fluorouracil, and oxaliplatin] or FOLFIRI [leucovorin, fluorouracil, and irinotecan] intravenously every 2 weeks with or without intravenous bevacizumab or cetuximab). Patients and investigators were not masked to treatment assignment. The primary endpoints were progression-free survival (previously reported) and overall survival (data to be reported at the time of the final analysis). HRQOL outcomes were evaluated as prespecified exploratory endpoints. The analysis population comprised all randomly assigned patients who received at least one dose of study treatment and completed at least one HRQOL assessment. HRQOL outcomes were mean change from baseline to prespecified week 18 in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Quality of Life Questionnaire-Colorectal 29 (EORTC QLQ-CR29) scale and item scores, and in the EuroQoL 5 Dimensions 3 Levels (EQ-5D-3L) visual analogue scale and health utility scores; the proportion of patients with improved, stable, or deteriorated scores from baseline to prespecified week 18 in EORTC QLQ-C30 scales and items; and time to deterioration in EORTC QLQ-C30 global health status/quality of life (GHS/QOL), physical functioning, social functioning, and fatigue scores and EORTC QLQ-CR29 urinary incontinence scores. The threshold for a small and clinically meaningful mean difference in EORTC QLQ-C30 score was 5-8 points. This study is registered with ClinicalTrials.gov, NCT02563002 and is ongoing; recruitment is closed.Between Feb 11, 2016, and Feb 19, 2018, 307 patients were enrolled and randomly assigned to receive pembrolizumab (n=153) or chemotherapy (n=154). The HRQOL analysis population comprised 294 patients (152 receiving pembrolizumab and 142 receiving chemotherapy). As of Feb 19, 2020, median time from randomisation to data cutoff was 32·4 months (IQR 27·7-37·8). Least squares mean (LSM) change from baseline to prespecified week 18 showed a clinically meaningful improvement in EORTC QLQ-C30 GHS/QOL scores with pembrolizumab versus chemotherapy (between-group LSM difference 8·96 [95% CI 4·24-13·69]; two-sided nominal p=0·0002). Median time to deterioration was longer with pembrolizumab versus chemotherapy for GHS/QOL (hazard ratio 0·61 [95% CI 0·38-0·98]; one-sided nominal p=0·019), physical functioning (0·50 [95% CI 0·32-0·81]; one-sided nominal p=0·0016), social functioning (0·53 [95% CI 0·32-0·87]; one-sided nominal p=0·0050), and fatigue scores (0·48 [95% CI 0·33-0·69]; one-sided nominal p<0·0001).Pembrolizumab monotherapy led to clinically meaningful improvements in HRQOL compared with chemotherapy in patients with previously untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. These data, along with the previously reported clinical benefits, support pembrolizumab as a first-line treatment option for this population.Merck Sharp & Dohme, a subsidiary of Merck & Co, Kenilworth, NJ, USA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ShellyMaya完成签到 ,获得积分10
刚刚
1秒前
一只大憨憨猫完成签到,获得积分10
1秒前
JJ完成签到,获得积分10
1秒前
DrW完成签到,获得积分10
1秒前
隐形曼青应助yue采纳,获得10
2秒前
ccyy完成签到 ,获得积分10
2秒前
NexusExplorer应助腾腾腾采纳,获得10
3秒前
宿帅帅完成签到,获得积分10
4秒前
4秒前
Ningxin完成签到,获得积分10
4秒前
HHEHK发布了新的文献求助10
4秒前
柚子完成签到 ,获得积分10
4秒前
雨辰完成签到,获得积分10
6秒前
宿帅帅发布了新的文献求助10
6秒前
量子星尘发布了新的文献求助10
9秒前
9秒前
熠熠完成签到,获得积分10
9秒前
10秒前
zxzb完成签到,获得积分10
12秒前
苹果萧完成签到 ,获得积分10
15秒前
宋江他大表哥完成签到,获得积分10
15秒前
able发布了新的文献求助10
15秒前
王先生完成签到 ,获得积分10
16秒前
H.发布了新的文献求助10
16秒前
luoluo完成签到,获得积分10
17秒前
17秒前
高分子完成签到,获得积分10
17秒前
yian发布了新的文献求助10
18秒前
yar应助体贴凌柏采纳,获得10
19秒前
自由的雪一完成签到,获得积分10
19秒前
Ava应助李振博采纳,获得200
19秒前
JW发布了新的文献求助10
20秒前
无限的千凝完成签到 ,获得积分10
21秒前
CipherSage应助YeeYee采纳,获得10
21秒前
21秒前
Ander完成签到 ,获得积分10
22秒前
化白完成签到,获得积分10
23秒前
H.完成签到,获得积分10
23秒前
chuzihang完成签到 ,获得积分10
23秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038303
求助须知:如何正确求助?哪些是违规求助? 3576013
关于积分的说明 11374210
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029